T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes. The role of thymic microenvironmental cells and stromal factors in thymocyte malignant transformation and T-ALL development remains little explored. Here, using the TEL-JAK2 transgenic (TJ2-Tg) mouse model of T-ALL, which is driven by constitutive JAK/STAT signaling and characterized by the acquisition of Notch1 mutations, we sought to identify stromal cell alterations associated with thymic leukemogenesis. Immunofluorescence analyses showed that thymic lymphomas presented epithelial areas characterized by keratin 5 and keratin 8 expression, adjacently to keratin-negative, epithelialfree areas. Both keratin-positive and -negative areas stained conspicuously with ER-TR7 (a fibroblast marker), laminin, and CD31 (an endothelial cell marker). Besides keratin 5, keratin-positive areas were also labeled by the Ulex Europaeus agglutinin-1 medullary thymic epithelial cell (TEC) marker. To assess whether TECs are important for T-ALL development, we generated TJ2-Tg mice heterozygous for the FoxN1 transcription factor nude null mutation. In contrast to nude homozygous mice, which lack thymus and thymocytes, heterozygous mutant mice present only mild thymocyte maturation defects. In TJ2-Tg;Foxn1 +/nu compound mice both emergence of malignant cells in pre-leukemic thymi and overt T-ALL onset were significantly delayed. Moreover, in transplantation assays leukemic cell expansion in the thymus of recipient Foxn1 +/nu mice was reduced as compared to control littermates.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy thought to arise from the transformation of thymocytes, as supported by similarities in the immunophenotypic, genotypic and transcriptomic profile of T-ALL cases and specific stages of intrathymic T-cell differentiation (1) (2) (3) . During intrathymic thymocyte differentiation, transformation events can lead to aberrant expression of oncogenic transcription factors that induce maturation arrest (4) . Genetic abnormalities in T-ALL, which include chromosomal translocations, point mutations, and deletions (4) , typically result in the activation of signaling pathways commonly involved in cancer, most notably the PTEN/PI3K/AKT, Ras/MAPK and JAK/STAT pathways (5) . Furthermore, one of the most common genetic alterations and considered a hallmark of T-ALL are NOTCH1-activating point mutations, present in more than 60% of cases (4, 5) . The same signaling pathways that are activated by intrinsic oncogenic mutations can also be activated by extrinsic signals provided by stromal cells in organs
where T-ALL cells thrive. For example, despite the frequent presence of Notch1 mutations, T-ALL cells were shown to respond to and be maintained in vitro by NOTCH ligands, such as Delta-like ligand 1 and 4 (6) (7) (8) .
Several extrinsic factors promoting T-ALL growth in vitro and in vivo were identified, including interleukin (IL)-7 (9-11), IL-18 (12) , insulin-like growth factor (IGF)-1 (13) , ICAM-1 (14) and CXCL12 (15, 16) . However, it remained unclear to what extent T-ALL development depends on signals from its native thymic microenvironment. In this regard, thymectomy experiments in mouse models have since long hinted that the thymic microenvironment was essential for T-cell acute leukemia/lymphoma (17, 18) . Early reports indicated that stromal signals are important for leukemia maintenance, as the physical contact with thymic microenvironmental cells was shown to improve survival of co-cultured thymic-derived rodent primary leukemic T cells (19, 20) . Furthermore, histological and immunophenotypical studies showed that the thymic stroma undergoes profound alterations throughout thymic leukemogenesis in mice (21) (22) (23) . Supportive of the role of the thymic microenviroment in human T-cell leukemogenesis, several T-ALL patients present thymic enlargement at diagnosis (24, 25) . Moreover, patient cells were shown to expand in alymphoid fetal thymic organ cultures from NOD/SCID mouse without supplementation of exogenous factors (26) .
Thymocyte development is achieved through a well-orchestrated bidirectional communication (so-called thymic crosstalk) between stromal cells and maturing thymocytes. These interactions trigger molecular changes in the thymic stromal microenvironment that are essential for thymocyte migration, differentiation and selection of functional mature T cells tolerant to self-antigens (27) . The thymic microenvironment is composed of epithelial, mesenchymal, endothelial and hematopoietic cells (B lymphocytes, dendritic cells and macrophages). Thymic epithelial cells (TEC) are essential for the architecture of the embryonic and post-natal thymus, as demonstrated by genetic inactivation of the transcription factor FoxN1, an essential master regulator of TEC differentiation (28, 29) . The spatial organization of the thymus into compartments is associated with functionally different TEC subpopulations that are involved in the generation of successive stages of thymocyte development (30) . Of note, cortical TEC (cTEC) are involved in the positive selection of thymocytes expressing functional T-cell receptor complexes, while medullary TEC (mTEC) are important for the generation of self-tolerant mature T cells. This function is mediated through MHC class II-mediated presentation of tissue-restricted self-antigens, which are essential for the negative selection of auto-reactive thymocytes and the generation of regulatory T cells (31) .
The thymic molecular and cellular players involved in stromal support of thymocyte leukemogenesis have only recently began to be explored. Our group has reported that stromal cell inactivation of the RelB transcription factor and the TNF receptor superfamily member lymphotoxin-β receptor (LTβR), both components of the noncanonical NF-κB signaling pathway, delayed leukemia development in the TEL-JAK2 transgenic (TJ2-Tg) mouse model (32, 33) . Recently, Triplett and colleagues (34) found in another T-ALL mouse model that IGF1R was highly expressed by malignant cells and that high IGF-1 secretion by tumor-associated thymic dendritic cells (DCs) favored leukemic cell survival. Together, these data suggest that thymic microenvironmental cells participate in the development of T-cell leukemia.
In the present study, we characterized the thymic stromal alterations at various stages of disease and found that thymic leukemogenesis was associated with an increase in mTEC but not cTEC molecular markers. More importantly, we found that haploinsufficiency of the Foxn1 gene delayed thymic leukemogenesis.
Materials and methods

Mice
Mice were bred and maintained at the CBMR/University of Algarve barrier animal facility (HEPA filtration of incoming air, differential pressure, and disinfection or sterilization of room equipment and supplies), under 12 h light/dark cycles, and with autoclaved food ( 
Flow Cytometry
Single-cell suspensions from collected organs were prepared in PBS by tissue dissociation against a 
Immunofluorescence
Whole thymi were included and frozen in OCT compound (VWR, Radnor, PA, USA). Thymic cryosections of 6-10 µm were dried at 37ºC for 30 min before fixation with pre-cold acetone for 10 min 
Genomic DNA extraction and Notch1 mutation detection
Genomic DNA was extracted from TJ2-Tg leukemic cells using the GeneJET Genomic DNA purification kit (Thermo Fisher Scientific), following the manufacturer's protocol. The exon 34 of Notch1 was PCR amplified as previously described (36) , and purified PCR products were sequenced at the CCMAR-Centre of Marine Sciences sequencing facility (Faro, Portugal).
Next Generation Sequencing
Thymic stromal cell-enriched fractions from WT (5 male) and TJ2-Tg (1 female and 2 male) mice were obtained as described above and total RNA was extracted using the Direct-zol RNA Miniprep kit (Zymo Research). Next, mRNA was isolated using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, Ipswich, MA, USA), following the manufacturer's instructions. The WT and TJ2-Tg mRNA samples were pooled and purified using the RNeasy MinElute Cleanup kit (Qiagen) and further processed using the Ion Total RNA-Seq kit v2 (Thermo Fisher Scientific).
Sequencing was performed on Ion Torrent PGM (Thermo Fisher Scientific) using Ion 316 Chip kits v2 (Thermo Fisher Scientific) for the WT and TJ2-Tg pooled samples. Both FastQC and Prinseq indicated high sequence quality except for a residual adapter sequence in a subpopulation of reads. The latter was removed by Cutadapt software. Additionally, reads were trimmed when the corresponding Phred score fell below 25. Subsequently, reads were aligned to the full mouse genome (UCSC, version mm10) by the Torrent Mapping Alignment Program (TMAP). In total, 3,204,955 WT and 3,125,039
TJ2-Tg reads were mapped to the mouse genome. Gene expression levels were obtained by HTseqcount, and differential gene expression was assessed with Bioconductor package edgeR.
Statistical analysis
Graphs and statistical analyses were performed with GraphPad Prism software (La Jolla CA, USA).
Statistical tests are indicated in the figure legends. Two-tailed t-tests were used to determine how significant were the differences between the means of two independent samples. Welch's correction was applied when variances were unequal, as determined by the F-test.
Results
TEL-JAK2 mouse thymic lymphomas present profound structural changes as compared to healthy thymi
Thymic lymphomas from TJ2-Tg mice often become 10-20 times larger than age-matched control thymi and lose the typical thymic compartmentalization in cortex and medulla (35, 37) . To determine whether the thymic microenvironment influences TJ2-Tg-induced leukemogenesis, we began by assessing the spatial distribution of several thymic stromal cells in diseased mice.
Immunofluorescence analysis of thymic cryosections with antibodies against the keratin (Krt) 5 and
Krt8 epithelial cell markers revealed large cellular regions that lack Krt5-and Krt8-labeling, here designated as keratin-negative areas (KNA) (Supplementary Figure 1A As reported, fibroblast labeling by the ER-TR7 antibody was not restricted to any particular region of the WT thymus, but was more abundant in the thymic capsule, trabeculae, and lining of blood vessels (Figure 1 , panels d1 and d2) (39) . In TJ2-Tg thymic lymphomas, the pattern of ER-TR7 expression was similar in both keratin-positive and -negative areas, although a layer of ER-TR7 + cells marked the border between these two areas (Figure 1 , panels l1 and l2, and Supplementary Figure 2A ). The expression pattern of laminin labeling was similar to the ER-TR7 labeling, in that it was present throughout the tumor tissue, irrespective of keratin labeling, and bordering keratin-positive and -negative areas (Figure 1 , panels m1 and m2). The CD31 marker, labeling endothelial cells, was also present throughout the thymic lymphoma tissue (Figure 1 , panels n1 and n2). Double immunofluorescence analyses showed that all CD31 + lymphoma blood vessels were surrounded by laminin ( Supplementary Figure 2B) , which is normally a component of vascular basement membranes (40) .
While F4/80 + macrophages were scattered in normal thymic tissue (Figure 1 , panels g1 and g2), these cells were also distributed throughout TJ2-Tg thymic lymphomas, albeit more abundantly in keratin-positive areas (Figure 1 , panels o1 and o2). Finally, we also analyzed the distribution pattern of the integrin-binding ICAM-1 adhesion molecule. As previously reported (41, 42) , ICAM-1 was detected both in the thymus cortex and medulla, although more prominently in the latter (Figure 1, panel h1 ). In TJ2-Tg thymic lymphomas, ICAM-1 expression was more prevalent in areas of stronger Krt5 labeling ( Figure 1 , panels p1 and p2), often co-localizing at the cellular level (Supplementary Figure 2C) .
These data indicate that thymic lymphoma mTEC-like cells, like normal mTECs, express ICAM-1.
The immunohistological analyses indicated that TEC subpopulations undergo profound alterations in spatial distribution and organization upon lymphoma development. Gene expression analysis of whole TJ2-Tg thymic lymphomas revealed a significant decrease of Krt5 and Krt8 transcripts as compared to normal whole thymi, providing further indirect evidence that the proportion of epithelial cells within lymphomas was reduced ( Supplementary Figure 3) . Furthermore, the ratio of Krt5/Krt8 mRNA levels was significantly higher in TJ2-Tg thymic lymphomas than in normal thymi ( Supplementary Figure 3) , thus supporting the notion that the mTEC/cTEC ratio is enhanced in those tumors.
To gain insights into the dynamics of stromal cell alterations during TJ2-Tg disease, we performed immunohistology on smaller TJ2-Tg thymic lymphomas, i.e. weighing ≤240 mg (mean of 166 mg; n=4) as opposed to ≥589 mg (mean of 903 mg; n=4) described above. These analyses led to two main findings: first, Krt5 labeling was expanded in relation to Krt8 labeling, with concomitant loss of the normal cortico-medullary compartmentalization (Figure 2A , second row panels); second, the extension of KNAs, which contained abundant ER-TR7 + fibroblasts, increased with lymphoma size (Figure 2A , third row panels). Since an evident expansion of Krt5 + in relation to Krt8 + areas was recurrently detected in TJ2-Tg thymic lymphomas, we have also immunostained thymic lymphomas for the UEA-1 medullary marker, and this led to a similar staining pattern as Krt5 (Figure 2A, bottom panels) . These results indicate that in small lymphomas Krt5 + UEA-1 + TECs expanded in detriment of Krt8 + TECs.
Global gene expression analysis reveals alterations in thymic stromal cell composition early in leukemogenesis
To gain further insights into the nature of the earliest stromal cell alterations in thymic leukemogenesis, we used a genome-wide transcriptomic approach. To this end, stromal cell-enriched thymic fractions were obtained from 8-to 10-week-old WT mice and TJ2-Tg mice with incipient disease, as defined by nearly normal sized thymi (<100 mg) and presence of low proportions (10-22%) of CD8 + CD25 + leukemic cells within the thymocyte population (not shown). Pilot experiments showed that the crude fractionation method applied led to enrichment of thymic stromal cell genes and depletion of thymocyte-specific genes in stroma-enriched fractions ( Supplementary Figure 4) . Upon
RNA extraction, pooled samples were subjected to high-throughput sequencing. Bioinformatic analyses disclosed 640 differentially expressed genes (DEGs), 199 upregulated in WT thymi (Supplementary Table 3 ) and 441 upregulated in TJ2-Tg thymi (Supplementary Table 4 ). As expected from the crude stromal fractionation, several genes differentially expressed between WT and TJ2-Tg samples most likely derive from non-excluded T lineage cells (e.g., Ptcra, Rag1, Rag2, Dntt, Themis, etc.). Nevertheless, many up-or downregulated genes were well-characterized stromal cell markers (e.g. Ccl25, Vim, Lepr, S100a4, Zbtb46, Xcl1, etc.). To know if the identified DEGs reflect imbalances in thymic stromal cell proportions, we investigated whether they matched genes specifically and uniquely expressed in particular thymic stromal cell subsets, as identified by Ki and colleagues (43) .
Interestingly, of 116 cTEC-specific genes, 17 were upregulated in WT compared to TJ2-Tg thymi whereas none was upregulated in TJ2-Tg compared to WT thymi ( Figure 2B and C, and Supplementary Table 5 ). These findings confirm that cTEC markers are downregulated during lymphomagenesis. In contrast, mTEC-specific genes were not significantly enriched in either WT or TJ2-Tg samples. In addition, we observed that several genes specific of Sirpα + DCs were upregulated in TJ2-Tg but not WT thymi ( Figure 2B and C and Supplementary Table 5 ). These data indicate that thymic leukemogenesis in TJ2-Tg mice is accompanied by alterations in TEC subset proportions and an increase in DCs.
Foxn1 haploinsufficiency delays the onset of TEL-JAK2-induced leukemia
To assess whether TECs play a role in thymic leukemogenesis, we generated TJ2-Tg mice lacking one Foxn1 allele, a gene crucial for TEC development and maintenance in a dose-dependent manner (28) . Mice carrying the Foxn1 nude mutation in heterozygosity presented normal proportions of thymocyte developmental stages (as defined by CD4, CD8, CD25 and CD44 expression), including those ranging from the CD4 − CD8 − CD25 + CD44 − double negative three (DN3) stage to the CD4 + CD8 + double-positive stage (Supplementary Figure 5A and B) , which are the main cellular targets for TJ2-Tg malignant transformation (37) . It was reported that pre-puberty Foxn1 +/nu mice present lower thymic weight than WT controls (28, 44, 45) . Since TJ2-Tg leukemia arises during adulthood, we analyzed older mice. Thus, we observed that 8 or 20 week-old Foxn1 +/nu mice presented slightly smaller thymi than Foxn1 +/+ littermates (1.1-1.3-fold difference) (Supplementary Figure 5B ), but no statistically significant differences in thymic weight were found when considering females alone or older mice (7to 9-months) ( Supplementary Figure 5C and D) . Strikingly, comparison of Foxn1 +/+ and Foxn1 +/nu TJ2-Tg mouse cohorts showed that the onset of leukemia was delayed in TJ2-Tg mice with Foxn1 haploinsufficiency (7-week difference in median survival; hazard ratio of 2.93, with 95% CI of 1.90 to 4.51; Figure 3A ). Both TJ2-Tg;Foxn1 cohorts included both sexes, with an equal male-to-female ratio of 1.6:1. Survival analysis of each sex separately revealed that Foxn1 haploinsufficiency delayed leukemia onset in both settings ( Figure 3B ). Despite the different survival rates of the two cohorts, no significant differences were observed regarding end-stage tumor load ( Figure 3C ). Moreover, endstage TJ2-Tg;Foxn1 +/nu thymic lymphomas displayed KNAs and areas of overlapping Krt5 and Krt8 staining as control lymphomas (Supplementary Figure 6 ). Like in other T-ALL mouse models, TJ2-Tg leukemic cells were found to acquire activating frameshift mutations in the Notch1 exon 34, encoding the PEST domain (>65% incidence) (Supplementary Table 6 ). Notch1 PEST domain heterozygous mutations, as illustrated by the simultaneous detection of WT and mutated sequences ( Supplementary   Figure 7) , were also detected, with similar frequency, in leukemic cells from both Foxn1 haploinsufficient and control TJ2-Tg mice ( Table 1 ). These mutations consisted of deletions and/or insertions, often affecting the previously reported exon 34 hotspots (codons 2361 and 2398/99) (46, 47) and leading to premature stop codons and predicted loss of the C-terminal PEST domain (Table 1) . Together, these data indicate that FoxN1 insufficiency delayed leukemogenesis without influencing the outcome of disease evolution.
To investigate whether Foxn1 haploinsufficiency delayed the early stages of leukemogenesis at the cellular level, we monitored disease emergence in young pre-disease TJ2-Tg mice through detection of CD8 + CD25 + leukemic cells within total thymocytes, ( Figure 3D ). At this age, leukemic cells can be detected in TJ2-Tg thymi without significant organ enlargement (33) . Indeed, thymic weight in the analyzed Foxn1 +/+ and Foxn1 +/nu TJ2-Tg mice was not significantly different and it did not correlate with the percentage of detected CD8 + CD25 + leukemic cells ( Figure 3E ). However, thymi from TJ2-Tg;Foxn1 +/nu mice displayed a significantly lower percentage of CD8 + CD25 + cells than TJ2-Tg;Foxn1 +/+ thymi (7.8-fold difference; Figure 3F ). At this age, leukemic cells are detectable mainly in the thymus (33) . Although low percentages of CD8 + CD25 + cells could be detected in the blood, bone marrow and spleen of some mice, those were not significantly different among Foxn1 genotypes ( Figure 3F and not shown). These findings indicate that leukemic cell emergence is delayed when Foxn1 dose is reduced in TEC.
Although Foxn1 haploinsufficiency leads to a mild decrease in thymic size, which could contribute to the observed delayed leukemogenesis, the above-presented data suggest that reduction in FoxN1 expression levels in TECs has a more marked impact on leukemogenesis than on thymocyte generation and differentiation.
The Foxn1-dependent thymic microenvironment facilitates leukemic cell expansion
To determine the role of the Foxn1-dependent microenvironment in leukemia maintenance, leukemic cells were collected from diseased TJ2-Tg mice and infused into nonconditioned syngeneic Foxn1 +/nu and Foxn1 +/+ littermate controls ( Figure 4A ). When manifesting signs of disease, recipient mice were killed for macroscopic and flow cytometry analyses. Thymi from all recipient mice became infiltrated by CD8 + CD25 + leukemic cells ( Figure 4B ). Two independent experiments using either male or female recipients were performed and each individually revealed a trend towards lower tumor load in Foxn1 +/nu thymi ( Figure 4C ). Following normalization and data pooling, we found that Foxn1 +/nu mice displayed statistically significant lower thymic weight than Foxn1 +/+ littermates ( Figure 4D ). In contrast, the relative splenic and hepatic tumor load was not influenced by Foxn1 genotype (Figure 4D ). These results thus indicate that Foxn1 expression in TECs promotes leukemic cell expansion in the thymus.
Discussion
The malignant transformation of mouse or human thymocytes is triggered by the deregulation of key cellular mechanisms due to both cell-intrinsic genetic alterations and microenvironmental stimulation (48, 49) . Here, using a mouse model of JAK kinase-driven and Notch1-mutated T-ALL, we identified several microenvironmental cellular alterations associated with thymic lymphoma development and progression. These included shifts in expression of TEC markers, with loss of cortical and increase of medullary epithelial markers, together with increased proportions of fibroblasts, DCs and endothelial cells. Highlighting a role for TECs, we found that reducing the genetic dose of FoxN1, an essential TEC transcription factor in TEC differentiation, delayed thymic leukemogenesis.
Diseased TJ2-Tg mice present large thymic lymphomas with loss of cortico-medullary demarcation and frequent disruption of the thymic capsule (32, 35) . By performing immunohistological analyses against thymic keratin proteins, we observed that TJ2-Tg mouse thymic lymphomas developed conspicuous KNAs, which were more extensive in larger lymphomas. Similar observations were reported in thymic lymphomas from other mouse models (21, 34) . In TJ2-Tg mice, KNAs included fibroblasts and laminin-containing extracellular matrix, suggesting that leukemic cells first invade the capsular connective tissue before expanding outwardly, thus generating lymphomatous KNAs. By studying spontaneous thymic lymphomas of different sizes, we found that the normal cortico-medullary demarcation was always lost. This phenomenon was accompanied by a strong reduction in cortical (Krt8-positive, Krt5-negative) areas, which is in agreement with earlier reports of cortical atrophy and medullary expansion at pre-leukemic stages of viral-induced murine thymic lymphoma (22, 23, (50) (51) (52) .
Our data thus support the concept that upon emergence of leukemic cells in the thymus, these disseminate throughout all thymic compartments, impacting on TEC differentiation and/or distribution, before invading the thymic capsule and undergoing further expansion.
FoxN1 is a pivotal transcription factor for thymus and skin epithelial cell differentiation in rodents and humans (53) . However, its role in cancer is less understood. Previous evidence indicated that FoxN1 suppresses the transition from benign to malignant keratinocyte lesions (54) . Another report supporting a tumor-suppressive role for Foxn1 showed that its haploinsufficiency accelerated thymic leukemogenesis in the endogenous retrovirus-expressing AKR murine strain (55) . In contrast with these data, we found that loss of a single Foxn1 allele hindered both the onset of spontaneous TEL-JAK2-induced leukemia/lymphoma and the thymic expansion of leukemic cells in recipient mice. Since leukemogenesis in TJ2-Tg mice is initiated in the thymus (33, 37) and only TECs express Foxn1, we conclude that the delayed leukemogenesis in heterozygotes is caused by FoxN1-mediated defects dependent on these cells. Foxn1 haploinsufficiency was shown to cause a moderate reduction in thymic weight of pre-puberty mice (under 5 weeks) of different outbred and inbred strains (28, 44, 45) .
Young adult Foxn1 +/nu mice (8 and 20 weeks of age) displayed a mild reduction in thymic weight, which was less evident considering females alone or older mice, but no defects in the major Foxn1 +/nu thymocyte subsets were apparent. Further supporting the notion that delayed leukemogenesis caused by Foxn1 haploinsufficiency is not due to a mere decrease in thymocyte cellularity, the decrease in adult thymic weight caused by loss of one Foxn1 allele was much less pronounced (1.3-fold) relatively to the delay in both emergence of thymic leukemic cells (7.8-fold) and leukemia-related TJ2-Tg mouse death (2.2-fold higher mortality rate at 20 weeks of age). Although a putative role for reduced thymocyte cellularity cannot be formally excluded, our data indicate that the delayed thymic leukemogenesis caused by Foxn1 haploinsufficiency results from an as yet unidentified cellular mechanism acting specifically on leukemic cell propagation but not on thymocyte development.
Although the FoxN1-mediated mechanism fostering leukemogenesis remains unclear, it is possible that leukemic cell development is more sensitive than thymocyte development to changes in expression of specific FoxN1 target genes. In this line, we observed that Foxn1 haploinsufficiency was associated with a mild reduction in Ccl25 thymic expression (not shown), a well-established FoxN1 target gene (29, 56) and a potential T-ALL growth factor (57) . Future studies should address whether this or other FoxN1 target genes (e.g. Dll4 and Cxcl12) play direct roles in thymic leukemogenesis.
Alternatively, FoxN1 could impinge on leukemogenesis indirectly through changes in biological
properties of TECs or other thymic microenvironmental cells. Since thymic leukemogenesis is accompanied by a disorganization in TEC marker expression, it is possible that Foxn1 +/nu -associated TEC differentiation defects underlie the delayed leukemia onset in TJ2-Tg;Foxn1 +/nu mice. In addition, TECs were shown to regulate thymic vascularization (58, 59) , and thymic DC development, differentiation and recruitment (60) (61) (62) . Whether Foxn1 haploinsufficiency in TECs is linked to vascular or DC defects warrants further investigation.
It was previously shown that RelB and LTβR proteins, both expressed in mTEC and other thymic stromal cells, contribute to leukemogenesis (32, 33) . Additionally, these proteins are essential for thymic medulla development and maintenance, as shown by the impaired medullary compartment of the respective knock-out mice (63, 64) . The notion that RelB, LTβR and FoxN1 hinder leukemogenesis and that all are expressed in mTECs suggest that these or other medullary cell types are involved in thymic leukemogenesis.
Using a panel of thymic cell markers, we detected major organizational alterations involving several thymic stromal cell types at early and advanced stages of TJ2-induced leukemia. Most notably, we observed increased expression of CD31 and ER-TR7, markers for endothelial cells and thymic fibroblasts, respectively, suggesting that angiogenesis, fibroblast proliferation and accrued ECM deposition, which are often associated with cancer (65) may favor thymic lymphomagenesis, especially at the most advanced stages. We have also found expression of markers for macrophages (F4/80) and DCs (DEC205) in lymphomas. Macrophages have been identified in mouse thymic lymphomas (22, 51, 66) , and recent studies indicate that lymphoma-associated macrophages stimulate T-ALL proliferation in vitro (67) . Thus, the potential involvement of tumor-associated macrophages in 
